1Laboratoire d'hématologie, hôpital de la Côte de Nacre, CHU de Caen, Caen, France.
Treatment advances for chronic lymphocytic leukemia (CLL) offer new options for frontline and relapsed/refractory patients. TP53 status is crucial for guiding therapeutic strategies in CLL management.
Area of Science:
You might also read
Articles linked to this work by shared authors, journal, and citation graph.